

**propiverine hydrochloride 30 mg modified release capsule  
(Detrunorm<sup>®</sup> XL) (No. 340/07)**  
**Amdipharm PLC**

---

**Product Update**

12 January 2007

The Scottish Medicines Consortium has completed its assessment of the above product and advises the NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**propiverine hydrochloride 30 mg modified release capsule (Detrunorm XL<sup>®</sup>)** is accepted for use in NHS Scotland for the treatment of urinary incontinence, as well as urgency and frequency in patients who have idiopathic detrusor overactivity (overactive bladder).

For patients for whom propiverine is appropriate it allows once-daily dosing, compared to twice daily dosing with an existing solid oral dose formulation, at no increased cost.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 11 December 2006.*

**Chairman  
Scottish Medicines Consortium**